Renaissance Technologies’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-31,546
| Closed | -$380K | – | 4660 |
|
|
2022
Q1 | $380K | Sell |
31,546
-35,905
| -53% | -$388K | ﹤0.01% | 3359 |
|
|
2021
Q4 | $695K | Buy |
67,451
+36,833
| +120% | +$661K | ﹤0.01% | 2915 |
|
|
2021
Q3 | $992K | Sell |
30,618
-3,138
| -9% | -$102K | ﹤0.01% | 2555 |
|
|
2021
Q2 | $1.45M | Buy |
33,756
+9,833
| +41% | +$404K | ﹤0.01% | 2461 |
|
|
2021
Q1 | $1.17M | Buy |
23,923
+4,412
| +23% | +$242K | ﹤0.01% | 2542 |
|
|
2020
Q4 | $685K | Buy |
19,511
+5,774
| +42% | +$181K | ﹤0.01% | 2687 |
|
|
2020
Q3 | $558K | Buy |
13,737
+2,959
| +27% | +$116K | ﹤0.01% | 2773 |
|
|
2020
Q2 | $485K | Buy |
10,778
+2,691
| +33% | +$143K | ﹤0.01% | 2894 |
|
|
2020
Q1 | $433K | Buy |
8,087
+1,546
| +24% | +$121K | ﹤0.01% | 2831 |
|
|
2019
Q4 | $442K | Buy |
6,541
+649
| +11% | +$75.1K | ﹤0.01% | 2948 |
|
|
2019
Q3 | $1.11M | Buy |
5,892
+947
| +19% | +$217K | ﹤0.01% | 2555 |
|
|
2019
Q2 | $1.32M | Sell |
4,945
-129
| -3% | -$43.2K | ﹤0.01% | 2561 |
|
|
2019
Q1 | $1.92M | Buy |
5,074
+1,791
| +55% | +$600K | ﹤0.01% | 2322 |
|
|
2018
Q4 | $1.22M | Buy |
3,283
+215
| +7% | +$84.3K | ﹤0.01% | 2480 |
|
|
2018
Q3 | $1.32M | Buy |
3,068
+282
| +10% | +$119K | ﹤0.01% | 2490 |
|
|
2018
Q2 | $1.01M | Buy |
2,786
+340
| +14% | +$160K | ﹤0.01% | 2595 |
|
|
2018
Q1 | $1.12M | Buy |
2,446
+296
| +14% | +$147K | ﹤0.01% | 2615 |
|
|
2017
Q4 | $1.24M | Buy |
2,150
+316
| +17% | +$208K | ﹤0.01% | 2584 |
|
|
2017
Q3 | $1.39M | Buy |
1,834
+316
| +21% | +$250K | ﹤0.01% | 2456 |
|
|
2017
Q2 | $1.27M | Buy |
1,518
+197
| +15% | +$144K | ﹤0.01% | 2482 |
|
|
2017
Q1 | $932K | Buy |
1,321
+75
| +6% | +$52.9K | ﹤0.01% | 2566 |
|
|
2016
Q4 | $903K | Buy |
1,246
+113
| +10% | +$91.8K | ﹤0.01% | 2583 |
|
|
2016
Q3 | $1.08M | Buy |
1,133
+206
| +22% | +$260K | ﹤0.01% | 2527 |
|
|
2016
Q2 | $1.32M | Buy |
927
+269
| +41% | +$346K | ﹤0.01% | 2418 |
|
|
2016
Q1 | $811K | Buy |
658
+151
| +30% | +$174K | ﹤0.01% | 2676 |
|
|
2015
Q4 | $655K | Buy |
507
+136
| +37% | +$177K | ﹤0.01% | 2636 |
|
|
2015
Q3 | $538K | Buy |
371
+7
| +2% | +$13.5K | ﹤0.01% | 2601 |
|
|
2015
Q2 | $803K | Buy |
364
+89
| +32% | +$279K | ﹤0.01% | 2555 |
|
|
2015
Q1 | $819K | Buy |
275
+183
| +199% | +$586K | ﹤0.01% | 2405 |
|
|
2014
Q4 | $303K | Buy |
+92
| New | +$326K | ﹤0.01% | 2580 |
|
|
2014
Q1 | – | Sell |
-107
| Closed | -$399K | – | 3063 |
|
|
2013
Q4 | $399K | Buy |
107
+40
| +60% | +$152K | ﹤0.01% | 2421 |
|
|
2013
Q3 | $265K | Buy |
+67
| New | +$503K | ﹤0.01% | 2501 |
|
Other funds holding FRTX
TI
PCM
BTI
TSS
Renaissance Technologies's FRTX Position: Q2 2022 in Review
Renaissance Technologies sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q2 2022, closing a stake of 31,546 shares — an estimated $380K sold.
Renaissance Technologies first reported a position in FRTX in Q3 2013 and held it in 32 quarters. The position peaked at $1.92M in Q1 2019. 22 funds tracked by Wall St. Rank hold FRTX as of Q2 2022.
- Renaissance Technologies reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
- Renaissance Technologies sold 31,546 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $380K.
- Renaissance Technologies first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q3 2013 and held it in 32 quarters.
- Renaissance Technologies's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $1.92M in Q1 2019.
- 22 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q2 2022.
Based on Renaissance Technologies's 13F filing for Q2 2022, filed 12 Aug 2022.